Can octreotide cause bradycardia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Octreotide Cause Bradycardia?

Yes, octreotide can cause bradycardia and other cardiac conduction abnormalities, including arrhythmias and heart block, particularly when administered intravenously or as a bolus.

Cardiac Effects: Evidence from FDA Labeling and Guidelines

The FDA drug label for octreotide explicitly warns about cardiac function abnormalities 1. In clinical trials of acromegalic patients, sinus bradycardia (<50 bpm) developed in 25% of patients, conduction abnormalities occurred in 10%, and arrhythmias developed in 9% during octreotide therapy 1. The FDA specifically recommends cardiac monitoring in patients receiving octreotide intravenously and advises using the drug with caution in at-risk patients 1.

The 2019 ACC/AHA/HRS bradycardia guidelines acknowledge octreotide's cardiac effects, noting that bradycardia, arrhythmias, or conduction abnormalities may occur, and dosage adjustment of cardiac medications may be necessary 2. The 2022 oral octreotide review similarly lists bradycardia, arrhythmia, and conduction abnormalities as adverse effects requiring monitoring 3.

Clinical Context and Risk Factors

The risk of bradycardia appears highest with:

  • Intravenous bolus administration (particularly doses ≥100 mcg)
  • Rapid administration rather than slow infusion
  • Patients with pre-existing cardiac conduction disease
  • Concurrent use of AV-blocking agents (beta-blockers, calcium channel blockers)

Multiple case reports document severe cardiac complications. One case described complete heart block during octreotide infusion in a patient with cryptogenic cirrhosis, requiring temporary pacemaker placement 4. Another report documented Mobitz type II AV block and complete heart block following 100 mcg IV boluses during carcinoid tumor surgery 5.

Route and Dose Considerations

Subcutaneous administration appears safer than intravenous bolus dosing. A study of patients with congestive heart failure receiving subcutaneous octreotide (25-50 mcg) for sulfonylurea-induced hypoglycemia reported no cardiac adverse events, despite theoretical concerns in this high-risk population 6. The authors noted that adverse effects depend on route, dose, and formulation, with subcutaneous dosing for specific indications (like hypoglycemia) appearing safer than IV boluses 6.

The 2024 AGA clinical practice update on vasoactive drugs notes that octreotide can cause bradycardia and cardiac conduction abnormalities, listing these among the drug's adverse effects requiring monitoring 7.

Practical Management Recommendations

When administering octreotide:

  • Monitor ECG during IV administration, especially with bolus dosing
  • Administer IV boluses slowly when required (e.g., for carcinoid crisis)
  • Prefer continuous infusion over bolus when treating acute variceal hemorrhage—one study showed continuous infusion at 4 mg/24h was more effective than 2 mg boluses every 4 hours with fewer adverse events 7
  • Use caution in patients taking beta-blockers or calcium channel blockers—dose adjustments may be needed 1
  • Consider subcutaneous route for chronic indications when appropriate
  • Have atropine and pacing capability available when using IV octreotide in high-risk settings

Special Populations

Post-heart transplant patients warrant particular caution. One study found that 20% of heart transplant patients receiving atropine experienced paradoxical heart block or sinus arrest 2. While this specifically addresses atropine, it highlights the unpredictable cardiac responses in denervated hearts, suggesting octreotide should be used cautiously in this population.

The bradycardia risk is real and clinically significant, but can be managed with appropriate monitoring, careful dosing, and route selection. The benefits often outweigh risks when octreotide is used appropriately for its indicated conditions, but cardiac monitoring is essential, particularly with IV administration.

Related Questions

How long should octreotide be continued in a patient whose 24‑hour lymphatic output has decreased from 1600 ml to 609 ml over five days?
How should bradycardia and arrhythmias be managed in a patient receiving octreotide therapy?
How should octreotide (synthetic somatostatin analogue) be used to treat postoperative lymphorrhea?
Can native somatostatin be used as a substitute for octreotide in the management of postoperative lymphorrhea?
Can metoclopramide (Maxolon) be administered to a patient who is two days post‑gastric bypass with an intestinal obstruction?
Does the CT scan show signs of stroke or intracranial hemorrhage?
Please describe the normal distribution and positively skewed curves, define epidemiology, outline the levels of prevention (including quaternary with examples), explain pollution and water pollution prevention, summarize waste management and incineration advantages/disadvantages, list the immunization schedule, detail components of safe motherhood, define infant, compare comprehensive versus basic emergency services, describe Ghana's CHPS model, the responsibilities of a health‑system IT head, tools used by community health officers during home visits, stages of demographic transition, and differentiate a mushroom from the stationary phase of microbial growth.
Did the patient have a normal outcome?
Are there guidelines or evidence supporting the use of aspirin to reduce flushing caused by dimethyl fumarate or diroximel fumarate in patients with multiple sclerosis?
Can ribociclib (Kisqali) be given concurrently with curative‑intent radiation therapy, and should it be paused during treatment?
What does this non‑contrast CT head and CT angiography (CTA) of the head and neck report suggest as the likely cause of the patient’s mental‑status changes and dizziness?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.